- Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein for muco-obstructive lung diseases, at the European Respiratory Society (ERS) International Congress 2022.
- Inhibition of Jagged-1/Notch 2-dependent signaling has been shown to reduce the number of secretory cells in airways, thereby reducing goblet cell metaplasia and mucus hypersecretion in ex vivo and in vivo models.
- Also Read: Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs.
- Pieris has generated a suite of inhaled candidates against Jagged-1, including several high-affinity antagonists across different target epitopes and biparatopic constructs with enhanced potency.
- The preclinical data show that candidate molecules inhibit Jagged-1-induced Notch 2 signaling in a dose-dependent manner and demonstrate that PRS-400 reduces mucin expression ex vivo.
- Additionally, PRS-400 was found in vivo to reduce mucin gene expression and goblet cells in mice with IL-13-induced airway inflammation.
- The company says that PRS-400 represents a promising inhalable therapeutic drug in muco-obstructive respiratory diseases.
- Price Action: PIRS shares are up 2.90% at $7.81 on the last check Wednesday.
Mizuho Maintains Neutral on Mid-America Apartment, Lowers Price Target to $166
Mizuho analyst Haendel St. Juste maintains Mid-America Apartment (NYSE:MAA) with a Neutral and lowers the price target from $177 to $166.
